JP Patent

JP5450381B2 — 化合物、そのような化合物を含有する組成物、及びそのような化合物を用いるがん及び自己免疫疾患の治療法

Assigned to プロメティック・バイオサイエンスィズ・インコーポレーテッド · Expires 2014-03-26 · 12y expired

What this patent protects

Patent listed against Rezlidhia.

Drugs covered by this patent

Patent Metadata

Patent number
JP5450381B2
Jurisdiction
JP
Classification
—
Expires
2014-03-26
Drug substance claim
No
Drug product claim
No
Assignee
プロメティック・バイオサイエンスィズ・インコーポレーテッド
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.